Gerhard Ehninger

Gerhard Ehninger

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 293 publications

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Journal: Nature medicine

Published: January 07, 2026

PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.

PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.

Journal: Annals of hematology

Published: October 08, 2025

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Journal: American journal of hematology

Published: August 18, 2025

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 18, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Journal: American journal of hematology

Published: June 25, 2025

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

Journal: Blood

Published: February 07, 2025

The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.

The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.

Journal: British journal of haematology

Published: November 18, 2024

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 16, 2024

ePROs in the routine care of a major oncology center: Results and experiences

ePROs in the routine care of a major oncology center: Results and experiences

Journal: Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Published: February 29, 2024

Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

Journal: Haematologica

Published: February 06, 2024

Showing 1-12 of 293

Last Updated: 09/26/2026